Citigroup Downgrades Sarepta Therapeutics to Neutral, Raises Price Target to $176
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang has downgraded Sarepta Therapeutics (NASDAQ:SRPT) from Buy to Neutral while raising the price target from $172 to $176.

June 26, 2024 | 2:27 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup analyst David Hoang downgraded Sarepta Therapeutics from Buy to Neutral, but raised the price target from $172 to $176.
The downgrade from Buy to Neutral suggests a less optimistic outlook on the stock's performance, which could lead to a neutral or slightly negative short-term impact. However, the raised price target to $176 indicates some underlying confidence in the company's value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100